研究设计与统计

订阅

MedSci主页 / 所有栏目 / 研究设计与统计

受试者招募及其依从性管理 CRC的职责

2014-04-25 MedSci MedSci原创

临床试验受试者
关注

受试者是临床试验中最主要的组成部分。试验需要什么样的受试者由方案的纳入／排除标准明确规定。受试者必须通过招募参与研究，一旦入组就必须积极参与整个临床试验。临床研究协调员（CRC ）的另一个重要职责就是与受试者之间的相互交流。 受试者                      &n

受试者是临床试验中最主要的组成部分。试验需要什么样的受试者由方案的纳入／排除标准明确规定。受试者必须通过招募参与研究，一旦入组就必须积极参与整个临床试验。临床研究协调员（CRC ）的另一个重要职责就是与受试者之间的相互交流。 受试者                                                 人们参加临床试验的动机是什么呢？佛吉尼亚联邦大学的一项调查显示，健康成年志愿者参加I期临床试验的主要原因是——金钱，然而不再参加后续研究的原因则是日程安排上的冲突。 除了金钱因素外，人们参加临床试验的其他原因有： 由内科医生建议作为一种治疗选择。 享受免费的医疗。 享受免费的药物。 没有其他治疗方法。 所提供的治疗方法可能改善患者的健康状况或延长寿命。 推动医学发展的奉献精神。 获得医疗教育。 无论出于什么动机，最重要的是

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827224, encodeId=6782182e224da, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Aug 26 06:37:00 CST 2014, time=2014-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319248, encodeId=08b81319248d4, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446077, encodeId=1f1414460e744, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543722, encodeId=4d9d1543e223c, content=<a href='/topic/show?id=fd8c380e6c6' target=_blank style='color:#2F92EE;'>#受试者招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38076, encryptionId=fd8c380e6c6, topicName=受试者招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577913601903, createdName=h.y200607_23674422, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548468, encodeId=242415484682d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
    2014-08-26 yxch36

    #CRC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1827224, encodeId=6782182e224da, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Aug 26 06:37:00 CST 2014, time=2014-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319248, encodeId=08b81319248d4, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446077, encodeId=1f1414460e744, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543722, encodeId=4d9d1543e223c, content=<a href='/topic/show?id=fd8c380e6c6' target=_blank style='color:#2F92EE;'>#受试者招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38076, encryptionId=fd8c380e6c6, topicName=受试者招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577913601903, createdName=h.y200607_23674422, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548468, encodeId=242415484682d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
    2014-04-27 fyxzlh

    #依从性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1827224, encodeId=6782182e224da, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Aug 26 06:37:00 CST 2014, time=2014-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319248, encodeId=08b81319248d4, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446077, encodeId=1f1414460e744, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543722, encodeId=4d9d1543e223c, content=<a href='/topic/show?id=fd8c380e6c6' target=_blank style='color:#2F92EE;'>#受试者招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38076, encryptionId=fd8c380e6c6, topicName=受试者招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577913601903, createdName=h.y200607_23674422, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548468, encodeId=242415484682d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
    2014-04-27 xinmeili

    #受试者#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1827224, encodeId=6782182e224da, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Aug 26 06:37:00 CST 2014, time=2014-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319248, encodeId=08b81319248d4, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446077, encodeId=1f1414460e744, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543722, encodeId=4d9d1543e223c, content=<a href='/topic/show?id=fd8c380e6c6' target=_blank style='color:#2F92EE;'>#受试者招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38076, encryptionId=fd8c380e6c6, topicName=受试者招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577913601903, createdName=h.y200607_23674422, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548468, encodeId=242415484682d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
    2014-04-27 h.y200607_23674422

    #受试者招募#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1827224, encodeId=6782182e224da, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Aug 26 06:37:00 CST 2014, time=2014-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319248, encodeId=08b81319248d4, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446077, encodeId=1f1414460e744, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543722, encodeId=4d9d1543e223c, content=<a href='/topic/show?id=fd8c380e6c6' target=_blank style='color:#2F92EE;'>#受试者招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38076, encryptionId=fd8c380e6c6, topicName=受试者招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577913601903, createdName=h.y200607_23674422, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548468, encodeId=242415484682d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Sun Apr 27 08:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
    2014-04-27 ms1260584454294838

    #招募#

    0

相关资讯

为什么要做临床试验？-如何通过临床试验来确定一种药物是否有效

最近网上有网友认为自己拥有了某种“效果特别好”的治疗哮喘的方法，他认为可以通过打赌的办法来判断出自己的方法要超过临床上普遍采用的治疗方案。但是，我必须很有把握的指出：现代临床医学的研究者门已经提供了一整套判断治疗方案是否有效的客观评估方法，虽然这套方法还在不停的完善过程中，但是在可预见的将来，打赌肯定会是会被排除在这套评价体系之外的。 每年，全世界有无数的科研工作者，通过自己的辛勤努

临床试验有关SOP汇总

临床试验方案修改SOP1. 申办者（包括药厂、CRO等）向中心药物临床试验办公室提出修改申请，填写“药物临床试验修改申请表”。2. 提供资料，包括：药物临床试验前研究资料，含试验药物的化学、药学、毒理学、药理学和临床的（包括以前的和正在进行的试验）资料和数据、研究者手册、试验药品药检报告、申办者资质证明、SFDA药物临床试验批文、试验方案和知情同意书（可以是初稿）。3. 药物临床试验办公室根据

假死技术（紧急保护和复苏）进入临床试验

    美国宾夕法尼亚，匹兹堡大学长老医院(UPMC Presbyterian Hospital)的科学家和医生，正计划进行一项无法提前安排的临床实验，该实验中研究者无法对参与者进行筛选，同时参与者还无法签署知情同意书。实验参与者必须是十名受了致命刀伤、枪伤的患者，而且必须是在大量失血、心力衰竭的情况下进行实验。研究者称之为“紧急保护和复苏”技术，也就是科幻小说里所谓

Nature：达菲已成战略储备资源？

近日，一群来自非营利组织的医学专家在分析了此前未发表过的临床试验结果后称，各国政府已在储备用于治疗季节性和流行性感冒的抗病毒药物上浪费了数十亿美元。 4年多来，总部位于英国牛津的国际循证医学协作组一直就抗病毒药物达菲的功效不断提出异议。起初，该组织只是针对可利用的、有限的公开数据进行分析。如今，通过和《英国医学杂志》合作获取到未发表的达菲临床试验全部数据，国际循证医学协作组发表了一份长达500

实施临床试验报告规范，提高临床试验透明度

临床试验是指以人为对象的前瞻性研究，预先将受试者或受试人群分配至接受一种或多种医疗干预，以评价医疗干预对健康结局的影响。其中“ 医疗干预 ” 包括但不仅限于药物，也包括细胞及其他生物制品、外科治疗、放射治疗、医疗器械、行为疗法、治疗过程的改变和预防保健等[1,2]。 1、临床试验信息透明化的必要性 临床试验是获得防病治病知识的必要途径，主要目的是不断改进预防、诊断和治疗方法，提

Nature：临床试验的不确定性的争鸣

　　前美国药物公司首席官呼吁对结果分析实施欺骗行为进行定罪。 　　Scott Harkonen 曾经一位制药经理人，也是社会精英，但是目前，他处于软禁状态，且面临着专业除名。其罪行为：歪曲科学数据。但是 Harkonen 本人却对美国最高法院反驳说他自己并没有歪曲任何数据。 　　在 2